Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyHealth Net Neo-Synalar topical coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentHealth NetPolicy CP PMN.167

    Neomycin/fluocinolone (Neo-Synalar) topical cream coverage criteria

    Customize your policy alerts

    Sign up for Health Net Policy CP PMN.167 alerts

    Get alerted when Policy CP PMN.167 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governs medical necessity and prior authorization criteria for Neo-Synalar topical cream for members across Commercial, HIM, and Medicaid lines of business.

    Policy Summary
    PayerHealth Net
    PolicyNeomycin/fluocinolone (Neo-Synalar) topical cream coverage criteria
    Policy CodePolicy CP PMN.167
    Change TypeNo material changes
    Effective Date12.01.18
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing diagnosis of a corticosteroid‑responsive dermatosis and failure of a formulary topical antibacterial at maximally indicated doses.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    14 daysApproval duration
    2 tubes / 120 gMax per course
    2–4x dailyDosing

    Coverage Criteria

    Initial Approval Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered when ALL of the following are met:

    Initial Approval

    • Diagnosis of a corticosteroid-responsive dermatosis (examples include eczema, psoriasis, poison ivy/oak/sumac, insect bites, atopic dermatitis, seborrheic dermatitis).
    • Failure of a formulary topical antibacterial product at up to maximally indicated doses (see Appendix B) unless clinically significant adverse effects are experienced or all such agents are contraindicated.
    • Dose limits

      • Two tubes per treatment course.
      • Does not exceed 120 g per treatment course.
    Approval duration: 14 days.

    Re-authorization is not permitted; members must meet initial approval criteria for any subsequent request.

    Other Diagnoses/Indications

    For uses not meeting initial criteria:

    Alternate pathways

    • If the drug is on the formulary/PDL for the relevant line of business, follow the no coverage criteria policy for that line (CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, CP PMN.255 for Medicaid).
    • If the drug is NOT on the formulary/PDL for the relevant line of business, follow the non-formulary policy for that line (CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, CP PMN.16 for Medicaid).
    • If the requested use (e.g., diagnosis, age, dosing regimen) is not listed in the policy’s section for non-authorized indications AND the initial approval criteria do not apply, refer to the off-label use policy for the relevant line of business (CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, CP PMN.53 for Medicaid).

    Requests for Neo-Synalar use for indications that are not FDA‑approved and are not specifically addressed in this policy will not be authorized unless the provider supplies sufficient documentation of efficacy and safety per the applicable off‑label use policy for the member's line of business (see CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP PMN.53 for Medicaid).

    Contraindications include known hypersensitivity to any component of the preparation. Do not use Neo‑Synalar in the external auditory canal when the tympanic membrane is perforated. No boxed warnings are reported for this product.

    Neo‑Synalar combines an antibiotic and corticosteroid for corticosteroid‑responsive dermatoses with secondary infection. The manufacturer notes that the combination has not been demonstrated to provide greater benefit than the steroid component alone after 7 days of treatment, so use beyond 7 days is generally not supported by evidence of added effectiveness.

    Coding and Dosing Limits

    inv-06: Maximum per treatment course
    Maximum per treatment courseTwo tubes per treatment course (equivalent to 120 g per treatment course)
    Approval duration14 days per treatment course
    Re-authorizationNot permitted; members must meet initial approval criteria for any new request
    inv-07: Maximum daily applications
    Maximum daily applications4 applications per day
    Typical dosing frequencyApply a thin film to affected area 2 to 4 times daily
    AdministrationTopical application as a thin film to affected area

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required — documentation must show initial approval criteria are met. Provider must submit supporting clinical documentation (e.g., office chart notes, lab results, other clinical information) that demonstrates the member meets all approval criteria.

    • Prior authorization required before coverage.
    • Supporting documentation must include office notes, relevant labs, and treatment history.
    Step Therapy

    Step Therapy Requirement

    Step therapy requirement: member must have failed a formulary topical antibacterial at up to maximally indicated doses prior to approval, unless there is a documented contraindication or clinically significant adverse effect. See Appendix B for examples and dosing limits of formulary topical antibacterial alternatives.

    • Failure of a formulary topical antibacterial at maximally indicated doses is required prior to approval.
    • Exceptions allowed for documented contraindication or clinically significant adverse effects.
    Documentation Required

    Required Documentation

    Required documentation — provider must submit supporting clinical documentation to demonstrate criteria are met.

    • Office chart notes describing diagnosis and prior therapies tried.
    • Laboratory results, if relevant to the diagnosis or safety monitoring.
    • Documentation of adverse reactions or contraindications if step therapy was bypassed.
    Denial Risk

    Denial Triggers

    Denial triggers — authorization may be denied if documentation is incomplete or if the requested use is a non‑FDA indication without sufficient off‑label evidence per applicable off‑label policies.

    • Lack of supporting documentation of diagnosis or prior therapy attempts.
    • Requests for non‑FDA approved indications without sufficient evidence per off‑label use policies (CP.CPA.09, HIM.PA.154, CPPMN.53, or evidence of coverage).

    Background

    Neo‑Synalar (neomycin/fluocinolone) is a topical cream that combines an antibacterial agent (neomycin) with a corticosteroid (fluocinolone) and is indicated for the treatment of corticosteroid‑responsive dermatoses with secondary infection. It is intended to address both inflammation and localized bacterial infection when those conditions coexist.

    Definitions

    inv-13: Neo-Synalar (neomycin/fluocinolone cream)
    Product descriptionNeo-Synalar is a topical cream combining an antibacterial (neomycin) and a corticosteroid (fluocinolone)
    IndicationFor treatment of corticosteroid-responsive dermatoses with secondary infection
    Clinical noteCombination has not been shown to provide greater benefit than the steroid component alone after 7 days of treatment
    Policy Summary
    PayerHealth Net
    PolicyNeomycin/fluocinolone (Neo-Synalar) topical cream coverage criteria
    Policy CodePolicy CP PMN.167
    Change TypeNo material changes
    Effective Date12.01.18
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing diagnosis of a corticosteroid‑responsive dermatosis and failure of a formulary topical antibacterial at maximally indicated doses.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dosing LimitsProvider Actions and RequirementsBackgroundDefinitions